Age- and Gender-Specific Dyslipidemia in Omani Young Adults: Metabolic Links to Cardiovascular Risk

ORIGINAL ARTICLE
Gulam Saidunnisa Begum, Anshoo Agarwal, Nida Suhail, Mariah N. Hafiz, Mohammed M. Jawad, Awadh Elkareem Abass, Shefa A. Hejazy

 
For citation: Begum GS, Agarwal A, Suhail N, Hafiz MN, Jawad MM, Abass AE, Hejazy SA. Age- and Gender-Specific Dyslipidemia in Omani Young Adults: Metabolic Links to Cardiovascular Risk. International Journal of Biomedicine. 2025;15(4):668-673. doi:10.21103/Article15(4)_OA3
 
Originally published December 5, 2025

Abstract: 

Background: Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease that often remains undiagnosed in young adults due to its asymptomatic nature. Early detection and management are crucial to preventing long-term complications. This study aimed to determine the prevalence and patterns of dyslipidemia among young adults and examine its association with age and gender.
Materials and Methods: A cross-sectional analysis was conducted among 1,436 individuals (742 females and 694 males). Lipid profiles were assessed using established clinical thresholds, and gender differences were analyzed with the chi-square test.
Results: Dyslipidemia was present in 69.8% of participants, with the most common abnormalities being high total cholesterol (41.2%), low HDL-C (36.4%), and high LDL-C (34.5%). Low HDL-C was more frequent in females, while males exhibited higher triglycerides and mixed dyslipidemia. Prevalence increased with age, from 53.8% in those aged 20–24 years to 76.6% in the group 36–40 years.
Conclusion: Dyslipidemia is highly prevalent among young adults, with gender-specific and age-related variations. These findings emphasize the importance of early screening, lifestyle modification, and public health interventions to mitigate future cardiovascular disease risk.

Keywords: 
cardiovascular risk • dyslipidemia • young adults
References: 
  1. Ghazwani M, Mahmood SE, Gosadi IM, Bahri AA, Ghazwani SH, Khmees RA. Prevalence of Dyslipidemia and Its Determinants Among the Adult Population of the Jazan Region. Int J Gen Med. 2023 Sep 18;16:4215-4226. doi: 10.2147/IJGM.S429462. PMID: 37745134; PMCID: PMC10516128.
  2. Blacher J, Gabet A, Vallée A, Ferrières J, Bruckert E, Farnier M, Olié V. Prevalence and management of hypercholesterolemia in France, the Esteban observational study. Medicine (Baltimore). 2020 Dec 11;99(50):e23445. doi: 10.1097/MD.0000000000023445. PMID: 33327276; PMCID: PMC7738064.
  3. Rifin HM, Lourdes TR, Ab Majid NL, Abd Hamid HA, Hasani WR, Ling MY, et al. Hypercholesterolemia prevalence, awareness, treatment and control among adults in Malaysia: the 2015 national health and morbidity survey, Malaysia.  Glob J Health Sci. 2018;10(11):10-5539. doi: 10.5539/gjhs.v10n7p11
  4. Akbartabar Toori M PhD, Kiani F MSc, Sayehmiri F PhD, Sayehmiri K PhD, Mohsenzadeh Y MD, Ostovar R PhD, Angha P MSc, Mohsenzadeh Y MSc. Prevalence of Hypercholesterolemia, High LDL, and Low HDL in Iran: A Systematic Review and Meta-Analysis. Iran J Med Sci. 2018 Sep;43(5):449-465. PMID: 30214097; PMCID: PMC6123550.
  5. Saeed E, Ali R, Jalal-ud-din M, Saeed A, Jadoon RJ, Moiz M. HYPERCHOLESTEROLEMIA IN PATIENTS OF ISCHEMIC STROKE. J Ayub Med Coll Abbottabad. 2015 Jul-Sep;27(3):637-9. PMID: 26721027.
  6. Huang C, Zhang WQ, Tang WW, Liu Y, Liu JX, Xu RH, Zhao SP, Wang TD, Huang XB. Prevalence and related factors of dyslipidemia among urban adults aged 35 to 79 years in Southwestern China. Sci Rep. 2021 Sep 2;11(1):17579. doi: 10.1038/s41598-021-96864-w. PMID: 34475467; PMCID: PMC8413428.
  7. Song PK, Li H, Man QQ, Jia SS, Li LX, Zhang J. Trends in Determinants of Hypercholesterolemia among Chinese Adults between 2002 and 2012: Results from theNational Nutrition Survey. Nutrients. 2017 Mar 15;9(3):279. doi: 10.3390/nu9030279. PMID: 28294966; PMCID: PMC5372942.
  8. Pappan N, Awosika AO, Rehman A. Dyslipidemia. 2024 Mar 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32809726.
  9. Abujbara M, Batieha A, Khader Y, Jaddou H, El-Khateeb M, Ajlouni K. The Prevalence of Dyslipidemia among Jordanians. J Lipids. 2018 Oct 28;2018:6298739. doi: 10.1155/2018/6298739. PMID: 30510803; PMCID: PMC6230384.
  10. Qi L, Ding X, Tang W, Li Q, Mao D, Wang Y. Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China. Int J Environ Res Public Health. 2015 Oct 26;12(10):13455-65. doi: 10.3390/ijerph121013455. PMID: 26516874; PMCID: PMC4627042.
  11. Khader YS, Batieha A, El-Khateeb M, Al Omari M, Ajlouni K. Prevalence of dyslipidemia and its associated factors among Jordanian adults. J Clin Lipidol. 2010 Jan-Feb;4(1):53-8. doi: 10.1016/j.jacl.2009.12.004. Epub 2009 Dec 22. PMID: 21122627.
  12. Raffee LA, Alawneh KZ, Ibdah RK, Rawashdeh SI, Zoghoul S, Ewais AS, Al-Mistarehi AH. Prevalence, Clinical Characteristics, and Risk Among Patients with Ischemic Heart Disease in the Young Jordanian Population. Open Access Emerg Med. 2020 Nov 16;12:389-397. doi: 10.2147/OAEM.S272961. PMID: 33235526; PMCID: PMC7678703.
  13. Islam SM, Purnat TD, Phuong NT, Mwingira U, Schacht K, Fröschl G. Non-communicable diseases (NCDs) in developing countries: a symposium report. Global Health. 2014 Dec 11;10:81. doi: 10.1186/s12992-014-0081-9. PMID: 25498459; PMCID: PMC4267750.
  14. Al-Waili K, Al-Rasadi K, Zadjali F, Al-Hashmi K, Al-Mukhaini S, Al-Kindi M, Al-Sabti H, Al-Hinai AT, Farhan H, Al-Zakwani I. Clinical and Genetic Characteristics of Familial Hypercholesterolemia at Sultan Qaboos University Hospital in Oman. Oman Med J. 2020 Jun 30;35(3):e141. doi: 10.5001/omj.2020.59. PMID: 32704389; PMCID: PMC7362724.
  15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421. PMID: 12485966.
  16. Bonita R. Surveillance of Risk Factors for Non-Communicable Diseases. The WHO STEPwise Approach. Summary. 2001.
  17. Talpur MT, Katbar MT, Shabir KU, Shabir KU, Yaqoob U, Jabeen S, et al. Prevalence of dyslipidemia in young adults. Prof Med J. 2020;27(5):987-93. doi: 10.29309/TPMJ/2020.27.05.4040
  18. Qi L, Ding X, Tang W, Li Q, Mao D, Wang Y. Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China. Int J Environ Res Public Health. 2015 Oct 26;12(10):13455-65. doi: 10.3390/ijerph121013455. PMID: 26516874; PMCID: PMC4627042.
  19. Sadeghi M, Talaei M, Oveisgharan S, Rabiei K, Dianatkhah M, Bahonar A, Sarrafzadegan N. The cumulative incidence of conventional risk factors of cardiovascular disease and their population attributable risk in an Iranian population: The Isfahan Cohort Study. Adv Biomed Res. 2014 Nov 29;3:242. doi: 10.4103/2277-9175.145749. PMID: 25538928; PMCID: PMC4260292.
  20. Kargar S, Ansari H. Prevalence of dyslipidemias in the Middle East region: A systematic review & meta-analysis study. Diabetes Metab Syndr. 2023 Nov;17(11):102870. doi: 10.1016/j.dsx.2023.102870. Epub 2023 Oct 11. PMID: 37844434.
  21. Sessa WC. Estrogen Reduces LDL (Low-Density Lipoprotein) Transcytosis. Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2276-2277. doi: 10.1161/ATVBAHA.118.311620. PMID: 30354224; PMCID: PMC6448576.
  22. Penalva RA, Huoya Mde O, Correia LC, Feitosa GS, Ladeia AM. Lipid profile and intensity of atherosclerosis disease in acute coronary syndrome. Arq Bras Cardiol. 2008 Jan;90(1):24-30. English, Portuguese. doi: 10.1590/s0066-782x2008000100005. PMID: 18317637.
  23. Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, Chen ZY, Guo YL, Wu NQ, Yan SK, Wang ZW, Gao RL. 2023 China Guidelines for Lipid Management. J Geriatr Cardiol. 2023 Sep 28;20(9):621-663. doi: 10.26599/1671-5411.2023.09.008. PMID: 37840633; PMCID: PMC10568545.
  24.  He H, Yu YQ, Li Y, Kou CG, Li B, Tao YC, Zhen Q, Wang C, Kanu JS, Huang XF, Han M, Liu YW. Dyslipidemia awareness, treatment, control and influence factors among adults in the Jilin province in China: a cross-sectional study. Lipids Health Dis. 2014 Aug 3;13:122. doi: 10.1186/1476-511X-13-122. PMID: 25086650; PMCID: PMC4237893.
  25. Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne TL. Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Oct 18;165(8):560-564. doi: 10.7326/M16-0946. Epub 2016 Aug 9. PMID: 27538032.
  26.  Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998 Jun 4;338(23):1650-6. doi: 10.1056/NEJM199806043382302. PMID: 9614255.
  27. Thalib L, Zubaid M, Rashed W, Suwaidi JA, Almahmeed W, Alozairi E, Alanbaei M, Sulaiman K, Amin H, Al-Motarreb A. Impact of diabetic status on the hyperglycemia-induced adverse risk of short term outcomes in hospitalized patients with acute coronary syndromes in the Middle East: findings from the Gulf registry of Acute Coronary Events (Gulf RACE). Clin Med Res. 2011 Mar;9(1):32-7. doi: 10.3121/cmr.2010.946. Epub 2010 Sep 17. PMID: 20852085; PMCID: PMC3064757.
  28. Al Suwaidi J, Zubaid M, El-Menyar AA, Singh R, Rashed W, Ridha M, Shehab A, Al-Lawati J, Amin H, Al-Mottareb A. Prevalence of the metabolic syndrome in patients with acute coronary syndrome in six middle eastern countries. J Clin Hypertens (Greenwich). 2010 Nov;12(11):890-9. doi: 10.1111/j.1751-7176.2010.00371.x. Epub 2010 Aug 30. PMID: 21054777; PMCID: PMC8816483.
  29. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P; Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008 Nov;5(4):319-35. doi: 10.3132/dvdr.2008.046. PMID: 18958843.
  30. Hermans MP, Fruchart JC. Reducing Residual Vascular Risk in Patients with Atherogenic Dyslipidemia: Where do we go from here? Clin Lipidol. 2010;5:811-26 . doi: org/10.2217/clp.10.65
  31. Al-Rasadi K, Al-Zakwani I, Zubaid M, Ali A, Bahnacy Y, Sulaiman K, Al Mahmeed W, Al Suwaidi J, Mikhailidis DP. Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. Open Cardiovasc Med J. 2011;5:203-9. doi: 10.2174/1874192401105010203. Epub 2011 Aug 30. PMID: 21966331; PMCID: PMC3178900.
  32. Goldstein JK, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (editors). The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill Inc; 2001; p. 2863-913. 
  33. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004 Sep 1;160(5):407-20. doi: 10.1093/aje/kwh236. PMID: 15321837.

Download Article
Received October 8, 2025.
Accepted November 20, 2025.
©2025 International Medical Research and Development Corporation.